CorMedix (CRMD)
Sells an FDA-approved catheter lock solution and a portfolio of hospital anti-infective drugs across the US.
Something off on this page? Send us feedback.
Sells DefenCath, an antimicrobial catheter lock solution for dialysis patients, alongside a broader portfolio of hospital anti-infective drugs added through an acquisition, generating revenue primarily from US hospitals and outpatient dialysis providers.
Develops and commercializes anti-infective therapies for hospital and dialysis settings, anchored by DefenCath, an antimicrobial catheter lock solution that prevents bloodstream infections in patients on chronic hemodialysis through a central venous catheter — the first FDA-approved product of its kind in the US.
A subsequent acquisition of Melinta Therapeutics added a portfolio of marketed antibiotics for hospital-acquired infections, broadening the business beyond a single product into a diversified anti-infective franchise sold primarily to US hospitals and dialysis providers.
Originally organized around cardiorenal disease research, the company pivoted to the US anti-infective market after winding down its European operations, and DefenCath itself reached the market only after two manufacturing-related regulatory rejections delayed its approval by several years. Commercial performance depends on hospital and dialysis-center adoption, third-party manufacturing quality, and Medicare reimbursement mechanisms for outpatient dialysis use.
Company facts
Unavailable right now.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $256.7M · Total debt $145.2M · Total assets $904.1M · Shareholders' equity $460.8M
- Revenue
- $101.9M
- Operating income
- $42.9M
- Net income
- $26.0M
No dividends on record.
| Institutions205 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | ≈ 57.23% | 44.61M shares | |
| Insiders14 holders · as of Sep 1, 2026 | 8.99% | 7.01M shares | |
| Otherremainder | ≈ 33.78% | 26.33M shares |
77.94M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
BlackRock, Inc.Institution | 8.11% | 6.32M | 13Fas of Jun 30, 2026 |
Deep Track Capital, LPInstitution | 8.05% | 6.27M | 13Fas of Jun 30, 2026 |
Shaibatalhamd Aymen AbdalkaderInsider | 5.93% | 4.62M | 13Gfiled Jun 12, 2026 ↗ |
Vanguard Capital Management LLCInstitution | 4.02% | 3.14M | 13Fas of Jun 30, 2026 |
State Street CorpInstitution | 2.97% | 2.32M | 13Fas of Jun 30, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jan 21, 2026 | Janet Dillione | director | −10,000 | $6.88 |
| Dec 30, 2025 | Alan W. Dunton | director | −20,000 | $13.00 |
| Dec 18, 2025 | Joseph Todisco | director, officer: Chief Executive Officer | −30,000 | $12.00 |
| Dec 9, 2025 | Janet Dillione | director | −34,000 | $12.00 |
| Dec 9, 2025 | Steven W. Lefkowitz | director | −40,000 | $11.88 |
- Innoviva
Head-to-head in resistant Gram-negative hospital infections and HABP/VABP
- Merck
Head-to-head in carbapenem + beta-lactamase-inhibitor Gram-negative antibiotics
- AbbVie
Head-to-head in resistant Gram-negative hospital infections via Avycaz
- Gilead Sciences
Head-to-head in invasive fungal infections via AmBisome
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| CorMedix | $8.55 | −0.75% | $675.5M | 4.0 | — | 1.5 | +156.5% |
| Innoviva | $21.18 | −0.81% | $1.58B | 5.2 | 10.0 | 3.6 | +19.3% |
| Merck | $151.72 | +0.05% | $374.52B | 121.3 | 17.6 | 5.6 | +5.1% |
| AbbVie | $264.00 | +0.88% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Gilead Sciences | $149.20 | −0.27% | $185.75B | — | 16.5 | 6.1 | +10.2% |
| Median | 73.7 | 16.9 | 5.9 | +10.2% |